Taysha Announces Pricing of Public Offering of Common

DALLAS, Oct. 26, 2022 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, pivotal-stage gene remedy firm targeted on creating and commercializing AAV-based gene therapies for the remedy of monogenic ailments of the central nervous system (CNS) in each uncommon and enormous affected person populations, at this time introduced the pricing of an underwritten public providing of 14,000,000 shares of its widespread inventory at a value to the general public of $2.00 per share. In addition, Taysha has granted the underwriter a 30-day choice to buy as much as 2,100,000 further shares of widespread inventory on the public providing value, much less the underwriting low cost. The gross proceeds from the providing to Taysha are anticipated to be roughly $28.0 million, earlier than deducting underwriting reductions and commissions and different providing bills, excluding any train of the underwriter’s choice to buy further shares. The providing is anticipated to shut on or about October 31, 2022, topic to customary closing circumstances.

Goldman Sachs & Co. LLC is performing as sole book-runner for the providing.

A shelf registration assertion regarding the shares of widespread inventory supplied within the public providing described above was filed with the Securities and Exchange Commission (the “SEC”) on October 5, 2021 and declared efficient by the SEC on October 14, 2021. The providing is being made solely by means of a written prospectus and prospectus complement that kind an element of the registration assertion. A preliminary prospectus complement and accompanying prospectus regarding the providing has been filed with the SEC and is offered on the SEC’s web site at www.sec.gov. A remaining prospectus complement and accompanying prospectus shall be filed with the SEC. When accessible, copies of the ultimate prospectus complement and the accompanying prospectus may be obtained by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by phone at (866) 471-2526, or by e mail at [email protected] mail.gs.com.

This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase the securities being supplied, nor shall there be any sale of the securities being supplied in any state or different jurisdiction by which such supply, solicitation or sale can be illegal previous to the registration or qualification below the securities legal guidelines of any such state or different jurisdiction.

About Taysha Gene Therapies, Inc.

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS illness. With a singular deal with creating healing medicines, Taysha goals to quickly translate its remedies from bench to bedside. Taysha has mixed its workforce’s confirmed expertise in gene remedy drug growth and commercialization with the world-class UT Southwestern Gene Therapy Program to construct an in depth, AAV gene remedy pipeline targeted on each uncommon and large-market indications. Together, Taysha leverages its totally built-in platform—an engine for potential new cures—with a objective of dramatically bettering sufferers’ lives.

Forward-Looking Statements

This press launch comprises forward-looking statements inside the that means of the Private Securities Litigation Reform Act of 1995. Words equivalent to “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or comparable expressions are meant to determine forward-looking statements. Forward-looking statements embrace statements regarding the potential of Taysha’s candidates, together with its preclinical product candidates, to positively influence high quality of life and alter the course of illness within the sufferers Taysha seeks to deal with, its analysis, growth and regulatory plans for its product candidates, and Taysha’s public providing, together with anticipated gross proceeds and anticipated cut-off date, the uncertainties associated to market circumstances and the completion of the general public providing on the anticipated phrases or in any respect. Forward-looking statements are primarily based on administration’s present expectations and are topic to varied dangers and uncertainties that might trigger precise outcomes to vary materially and adversely from these expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements don’t represent ensures of future efficiency, and you might be cautioned to not place undue reliance on these forward-looking statements. Risks concerning Taysha’s business are described intimately in its SEC filings, together with in Taysha’s Annual Report on Form 10-Okay for the full-year ended December 31, 2021, and Taysha’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, each of which can be found on the SEC’s web site at www.sec.gov. Additional data shall be made accessible in different filings that Taysha makes infrequently with the SEC. Such dangers could also be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements converse solely as of the date hereof, and Taysha disclaims any obligation to replace these statements besides as could also be required by regulation.

Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies
[email protected]

Media Contact:
Carolyn Hawley
Evoke Canale
[email protected]